Regeneron and Sanofi secure historic seventh Japanese indication for Dupixent in bullous pemphigoid
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP) whose disease is not adequately controlled by existing therapies.



_1366493_640x360_2493295683757-640x360.webp&w=3840&q=75)
_1366482_640x360_2493293635741-640x360.webp&w=3840&q=75)
_1366465_640x360_2493286979711-640x360.webp&w=3840&q=75)

_1366447_640x360_2493285443755-640x360.webp&w=3840&q=75)

